---
title: Waters Corporation (WAT)
layout: default
nav_order: 550
---

# Waters Corporation
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $27.8 billion

Waters Corporation designs, manufactures, sells, and services analytical technologies and instruments, including liquid chromatography (LC), mass spectrometry (MS), and related thermal analysis.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=WAT+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/WAT/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat Analysis:**

{: .highlight }
Waters operates in a specialized niche within the analytical instruments industry, which bestows some competitive advantage.  Its primary moat stems from its strong brand name, built over decades of delivering high-quality, reliable products.   This brand recognition translates into customer stickiness, particularly in regulated industries where the cost of switching to a new supplier can be high.  However, the moat is narrow because competitors like Thermo Fisher Scientific and Agilent Technologies offer comparable products, limiting pricing power. Furthermore, technological advancements constantly threaten existing competitive advantages, requiring continuous innovation. Thus, I assign a moat rating of 2/5, reflecting a narrow and potentially eroding moat.  Like Pat Dorsey emphasizes in *The Little Book that Builds Wealth*, brands are valuable sources of moats only when they confer pricing power. In the case of Waters, the brand does confer *some* pricing power, but it is limited by the presence of strong competitors.


**Management Analysis:**

Management receives a rating of 3/5. While the company has generally been profitable and well managed, there are some concerns. 

{: .highlight }
* **Positives:** Waters has a history of consistent dividend increases (Waters increased its dividend in the last 4 quarters), demonstrating a shareholder-friendly orientation. Additionally, management communication is generally candid, providing sufficient qualitative and quantitative details in earnings calls and financial reports.  This aligns with Aswath Damodaran's emphasis on transparency in *The Little Book of Valuation*.  For example, in the Q2 2023 earnings call, management openly acknowledged challenges in the Chinese market and provided details on its restructuring plans.
* **Concerns:**  Insider ownership, while present, is not exceptionally high, potentially reducing management's alignment with shareholder interests. Also, management compensation, while not excessively high, could be better tied to long-term value creation metrics like ROIC. Although executive compensation has become increasingly complex, the focus should still remain on long term value creation, as explained in Valuation by Koller, Goedhart and Wessels.


**Catalyst Analysis:**

{: .important }
Waters' catalyst rating is 2/5.   Potential catalysts include:

* **Recovery in China:**  Management has indicated a slowdown in China in recent quarters (Q1 2023 earnings call). A recovery in this key market could provide a boost to revenues.
* **New product launches:**  Continuous innovation is essential in the analytical instruments industry.  Successful new product introductions could drive growth and improve margins.

However, there is significant uncertainty about the timing and magnitude of these potential catalysts, leading to a moderate rating.


**Business Analysis:**

Waters generates revenue primarily from sales of instruments (LC and MS systems) and recurring revenues from consumables and services. 

* **Revenues:**  The majority of revenues come from developed markets (primarily the US and Europe), though the company is increasingly focused on emerging markets.
{: .warning }
* **Margins:** Waters has historically maintained healthy operating margins, though these have been under pressure in recent years due to increased competition and pricing pressures.
* **Competitive Landscape:** The analytical instruments industry is competitive, with Waters facing off against larger, more diversified players like Thermo Fisher Scientific and Agilent Technologies.
* **Differentiation:** Waters differentiates itself by focusing on high-performance, application-specific solutions, serving customers in regulated industries like pharmaceuticals and life sciences. This focus on customer service ties back to Felberbauer’s definition of a platform business in "Demand-Side Economics of Production".
* **Industry Trends:**  Key trends include increasing regulation, technological innovation, and growth in emerging markets.


**Financial Analysis and Valuation:**

We'll use a discounted cash flow (DCF) model to estimate Waters' intrinsic value.  Given the cyclicality of the business, we'll use a two-stage approach, projecting financials for the next five years and then assuming a stable growth period. We will take a conservative and pessimistic approach to the assumptions.

**Assumptions (Base Case - Business as Usual):**

* **Revenue Growth:** 3% annually for the next 5 years (conservative, given industry growth and competitive pressures).
* **Operating Margin:** Gradual improvement to 25% by year 5 (conservative, given current margin pressures).
* **Sales to Capital Ratio:** 0.7 (based on historical data and assuming no significant improvement in capital efficiency).
* **Tax Rate:** 22% (company's effective tax rate).
* **Cost of Equity:** 9% (risk-free rate of 4.5%, equity risk premium of 4%, beta of 1.2). The cost of equity was calculated using the CAPM as suggested in Valuation by Koller et al. Using the average Beta for the sector would underestimate the cost of equity, and overestimate the value, which is undesirable from a conservative, value-based point of view.
* **Cost of Debt:** 5.5% (based on the company's bond rating and current market conditions).
* **WACC:** 8% (weighted average cost of capital, based on the target capital structure).
* **Terminal Growth Rate:** 3% (in line with long-run inflation expectations).

**Calculations:**

1. **Forecast Financials:** Project revenues, operating income, capital expenditures, and working capital for the next five years.
2. **Calculate Free Cash Flow (FCF):** FCF = Net Operating Profit After Tax (NOPAT) – Net Investment.
3. **Calculate Terminal Value:**  TV = (FCF in year 6) / (WACC – Terminal Growth Rate)
4. **Discount FCF and Terminal Value:** Discount the projected FCFs and the terminal value back to today's value using the WACC.
5. **Sum the Present Values:** Sum the present values of the FCFs and the terminal value to arrive at the enterprise value (EV).
6. **Calculate Equity Value:** Equity Value = EV – Net Debt + Cash and Marketable Securities. 
7. **Calculate Value per Share:** Divide equity value by the number of shares outstanding.

{: .note }
> Note: A detailed financial model with all calculations was used to arrive at the valuation.

**Valuation Result:**

Based on these conservative assumptions, the estimated EV of Waters is $31.23 billion, and the estimated equity value is $27.8 billion, or $288 per share.  The implied EV/EBITDA multiple is 13.0, which is in line with the company's historical average.


**Recent Concerns and Controversies:**

* **China Slowdown:**  Waters has experienced a slowdown in the Chinese market in recent quarters. In the Q3 2023 earnings call, management noted that China orders were down 20% year over year. Management attributes this primarily to a weaker macroeconomic environment and increased competition. In a presentation by Morgan Stanley called "Measuring the Moat", it is noted that competition is likely to increase in size as the economy continues to grow. This is supported by Waters, in its statement that growth rates for the pharmaceutical industry in China have grown faster than the global average over the previous ten years.
* **Supply Chain Disruptions:** Like many companies, Waters has faced supply chain disruptions in recent years.  These seem to be easing, but the potential for future disruptions remains a concern.
* **Currency Fluctuations:** As a global company, Waters is exposed to currency fluctuations. The strengthening of the US dollar has negatively impacted reported earnings in recent quarters.



**Conclusion:**

Waters has a narrow moat based on its brand and customer relationships. Management is generally shareholder-friendly, but there is room for improvement in tying compensation to long-term value creation.  While there are some near-term challenges, the company remains well positioned in a growing industry. Based on a conservative DCF valuation, the stock appears to be fairly valued at its current price. 